
Delta4 is a TechBio company specializing in AI-powered drug discovery and indication expansion. Their proprietary platform, Hyper-C, utilizes advanced algorithms and big data to identify undetected relationships between drugs with known safety profiles and new disease indications. This approach aims to discover and develop therapies faster, more cost-effectively, and with increased success rates compared to traditional methods. The platform de-risks the drug development process by leveraging existing safety data and provides a clear mechanism of action hypothesis, addressing the 'black box' problem often associated with AI. Delta4's process combines AI with the expertise of computational biologists to analyze data, generate insights, and move promising drug candidates through biological and clinical testing.

Delta4 is a TechBio company specializing in AI-powered drug discovery and indication expansion. Their proprietary platform, Hyper-C, utilizes advanced algorithms and big data to identify undetected relationships between drugs with known safety profiles and new disease indications. This approach aims to discover and develop therapies faster, more cost-effectively, and with increased success rates compared to traditional methods. The platform de-risks the drug development process by leveraging existing safety data and provides a clear mechanism of action hypothesis, addressing the 'black box' problem often associated with AI. Delta4's process combines AI with the expertise of computational biologists to analyze data, generate insights, and move promising drug candidates through biological and clinical testing.
Founded: 2019
Headquarters: Vienna, Austria
Focus: AI-powered drug discovery and indication expansion (Hyper-C platform)
Team size: Approximately 14 employees
Funding stage: Series A (Apr 2021 listed)
Drug discovery and indication expansion for rare/complex diseases (example: FSGS)
2019
Biotechnology
Series A entry appears on public profiles dated April 2021; specific investor names and amounts not disclosed in provided evidence.